Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net (VYNE Product Acquisition) (Details) $ in Thousands	Jan. 13, 2022 USD ($)
VYNE Product Acquisition [Member]
Indefinite-lived Intangible Assets [Line Items]
Consideration transferred at closing	$ 20,000
VYNE Product Acquisition [Member]
Indefinite-lived Intangible Assets [Line Items]
Deferred cash payment	$ 5,000
Percentage of upfront payments received on products outside the U.S. due to VYNE	10.00%
VYNE Product Acquisition [Member] \| Maximum [Member]
Indefinite-lived Intangible Assets [Line Items]
Sales-based milestone payments	$ 450,000
VYNE Product Acquisition [Member] \| Annual Sales Of $100 Million [Member]
Indefinite-lived Intangible Assets [Line Items]
Sales-based milestone payments	10,000
VYNE Product Acquisition [Member] \| Annual Sales Of $200 Million [Member]
Indefinite-lived Intangible Assets [Line Items]
Sales-based milestone payments	20,000
VYNE Product Acquisition [Member] \| Annual Sales Of $300 Million [Member]
Indefinite-lived Intangible Assets [Line Items]
Sales-based milestone payments	30,000
VYNE Product Acquisition [Member] \| Annual Sales Of $400 Million [Member]
Indefinite-lived Intangible Assets [Line Items]
Sales-based milestone payments	40,000
VYNE Product Acquisition [Member] \| Annual Sales Of $500 Million [Member]
Indefinite-lived Intangible Assets [Line Items]
Sales-based milestone payments	$ 50,000